期刊文献+

硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效分析 被引量:2

下载PDF
导出
摘要 目的分析应用硼替佐米联合地塞米松方法治疗多发性骨髓瘤的疗效。方法抽取确诊为多发性骨髓瘤的患者20例,对这些患者采取硼替佐米联合地塞米松的治疗方案。疗效评价标准为国际疗效评价标准,不良反应判断以美国国立癌症研究院不良事件通用名为依据。结果经过2~8个疗程治疗,18例患者对治疗有反应,在随访中发现这18例患者中,有12例获完全缓解,4例接近完全缓解,2例部分缓解。结论运用硼替佐米联合地塞米松治疗方案对多发性骨髓瘤进行治疗能够获得较好的治疗效果。
作者 陈艳波
出处 《航空航天医学杂志》 2015年第4期471-472,共2页 Journal of Aerospace medicine
  • 相关文献

参考文献4

二级参考文献23

  • 1袁振刚,侯健,周帆,王东星,付卫军,陈玉宝,奚昊,杨盛玲.硼替佐米联合地塞米松治疗16例复发、难治性多发性骨髓瘤患者[J].中华血液学杂志,2006,27(10):653-655. 被引量:21
  • 2Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma [J]. Br J Haematol, 2005,129 (6) : 776-783.
  • 3Richardson PG, Barlogie B, Berenson NJ, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [J]. N Engl J Med, 2003, 348 (26) : 2609 - 2617.
  • 4Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation [J]. Br J Haematol, 1998,102(5) : 1115-1123.
  • 5Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma [J]. Clin Cancer Res, 2004, 10 (12) : 3954-3964.
  • 6Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of conbinatious of bortezomih, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 2012, 119: 4375-4382.
  • 7Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is snperior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietie stem cell transplantation in patients with newly diagnosed muhiple myeloma. Blood, 2012, 120: 9-19,.
  • 8Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with reeurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer, 2008, 113: 765-771.
  • 9Ghobrial 1M, Weller E, Vii R, et al, Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol, 20! l, 12: 263-272.
  • 10Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leakemia, 2006, 20: 1467-1473.

共引文献9

同被引文献7

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部